A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with advanced Parkinson's disease. This novel treatment is the first of its kind,
Injectable drug to ease advanced Parkinson's disease symptoms approved by FDA
The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in study participants.
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.
Continuous Parkinson's Disease Therapy Wins FDA Nod
AbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly into the intestinal tract for 16 hours a day. The FDA recently rejected ND0612, a 24-hour-a-day liquid levodopa and carbidopa infusion from the Mitsubishi Tanabe Pharma subsidiary NeuroDerm.
FDA Approves AbbVie's Parkinson's Disease Drug Vyalev
Thursday said that the U.S. Food and Drug Administration (FDA) has approved Vyalev for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). The approval was supported by the pivotal phase 3 study evaluating Vyalev in adults with advanced PD compared to carbidopa/levodopa,
AbbVie says FDA has approved vyalev as first and only subcutaneous 24-hour infusion for adults with advanced Parkinson’s disease
AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson’s disease.
WebMD20h
FDA Approves New Treatment for Advanced Parkinson’s Disease
The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).
Pharmabiz4h
AbbVie’s Vyalev receives US FDA approval to treat adults living with advanced Parkinson's disease
Findings from the pivotal study showed patients receiving Vyalev demonstrated superior improvement in motor fluctuations, with increased "on" time without troublesome dyskinesia and decreased "off" ...
emjreviews.com8h
24-Hour Therapy for Parkinson’s: The First Of Its Kind
The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.
Medscape10d
Air Pollution Exposure and Risk for Parkinson's Disease and Dyskinesia: New Data
Increased exposure to nitrogen dioxide and particulate matter in the air was associated with an increased risk for ...
Business Insider26d
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
5 RIM-TD (Reducing Involuntary Movements in Participants with Tardive Dyskinesia) is a three-year study which enrolled patients who had completed one of the two pivotal deutetrabenazine phase 3 ...
Yahoo Finance1d
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
With data indicating an average increase of 2.72 hours against 0.97 hours for the oral version, VYALEV showed better growth ...
Medscape21h
FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s
Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease.